Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes

Shugo Tohyama, Fumiyuki Hattori, Motoaki Sano, Takako Hishiki, Yoshiko Nagahata, Tomomi Matsuura, Hisayuki Hashimoto, Tomoyuki Suzuki, Hiromi Yamashita, Yusuke Satoh, Toru Egashira, Tomohisa Seki, Naoto Muraoka, Hiroyuki Yamakawa, Yasuyuki Ohgino, Tomofumi Tanaka, Masatoshi Yoichi, Shinsuke Yuasa, Mitsushige Murata, Makoto SuematsuKeiichi Fukuda

Research output: Contribution to journalArticle

333 Citations (Scopus)

Abstract

Heart disease remains a major cause of death despite advances in medical technology. Heart-regenerative therapy that uses pluripotent stem cells (PSCs) is a potentially promising strategy for patients with heart disease, but the inability to generate highly purified cardiomyocytes in sufficient quantities has been a barrier to realizing this potential. Here, we report a nongenetic method for mass-producing cardiomyocytes from mouse and human PSC derivatives that is based on the marked biochemical differences in glucose and lactate metabolism between cardiomyocytes and noncardiomyocytes, including undifferentiated cells. We cultured PSC derivatives with glucose-depleted culture medium containing abundant lactate and found that only cardiomyocytes survived. Using this approach, we obtained cardiomyocytes of up to 99% purity that did not form tumors after transplantation. We believe that our technological method broadens the range of potential applications for purified PSC-derived cardiomyocytes and could facilitate progress toward PSC-based cardiac regenerative therapy.

Original languageEnglish
Pages (from-to)127-137
Number of pages11
JournalCell Stem Cell
Volume12
Issue number1
DOIs
Publication statusPublished - 2013 Jan 3

Fingerprint

Pluripotent Stem Cells
Cardiac Myocytes
Heart Diseases
Lactic Acid
Glucose
Culture Media
Cause of Death
Transplantation
Technology
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Medicine
  • Genetics

Cite this

Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. / Tohyama, Shugo; Hattori, Fumiyuki; Sano, Motoaki; Hishiki, Takako; Nagahata, Yoshiko; Matsuura, Tomomi; Hashimoto, Hisayuki; Suzuki, Tomoyuki; Yamashita, Hiromi; Satoh, Yusuke; Egashira, Toru; Seki, Tomohisa; Muraoka, Naoto; Yamakawa, Hiroyuki; Ohgino, Yasuyuki; Tanaka, Tomofumi; Yoichi, Masatoshi; Yuasa, Shinsuke; Murata, Mitsushige; Suematsu, Makoto; Fukuda, Keiichi.

In: Cell Stem Cell, Vol. 12, No. 1, 03.01.2013, p. 127-137.

Research output: Contribution to journalArticle

Tohyama, S, Hattori, F, Sano, M, Hishiki, T, Nagahata, Y, Matsuura, T, Hashimoto, H, Suzuki, T, Yamashita, H, Satoh, Y, Egashira, T, Seki, T, Muraoka, N, Yamakawa, H, Ohgino, Y, Tanaka, T, Yoichi, M, Yuasa, S, Murata, M, Suematsu, M & Fukuda, K 2013, 'Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes', Cell Stem Cell, vol. 12, no. 1, pp. 127-137. https://doi.org/10.1016/j.stem.2012.09.013
Tohyama, Shugo ; Hattori, Fumiyuki ; Sano, Motoaki ; Hishiki, Takako ; Nagahata, Yoshiko ; Matsuura, Tomomi ; Hashimoto, Hisayuki ; Suzuki, Tomoyuki ; Yamashita, Hiromi ; Satoh, Yusuke ; Egashira, Toru ; Seki, Tomohisa ; Muraoka, Naoto ; Yamakawa, Hiroyuki ; Ohgino, Yasuyuki ; Tanaka, Tomofumi ; Yoichi, Masatoshi ; Yuasa, Shinsuke ; Murata, Mitsushige ; Suematsu, Makoto ; Fukuda, Keiichi. / Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. In: Cell Stem Cell. 2013 ; Vol. 12, No. 1. pp. 127-137.
@article{05bd3b621eef4780877f2c383d98f9d2,
title = "Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes",
abstract = "Heart disease remains a major cause of death despite advances in medical technology. Heart-regenerative therapy that uses pluripotent stem cells (PSCs) is a potentially promising strategy for patients with heart disease, but the inability to generate highly purified cardiomyocytes in sufficient quantities has been a barrier to realizing this potential. Here, we report a nongenetic method for mass-producing cardiomyocytes from mouse and human PSC derivatives that is based on the marked biochemical differences in glucose and lactate metabolism between cardiomyocytes and noncardiomyocytes, including undifferentiated cells. We cultured PSC derivatives with glucose-depleted culture medium containing abundant lactate and found that only cardiomyocytes survived. Using this approach, we obtained cardiomyocytes of up to 99{\%} purity that did not form tumors after transplantation. We believe that our technological method broadens the range of potential applications for purified PSC-derived cardiomyocytes and could facilitate progress toward PSC-based cardiac regenerative therapy.",
author = "Shugo Tohyama and Fumiyuki Hattori and Motoaki Sano and Takako Hishiki and Yoshiko Nagahata and Tomomi Matsuura and Hisayuki Hashimoto and Tomoyuki Suzuki and Hiromi Yamashita and Yusuke Satoh and Toru Egashira and Tomohisa Seki and Naoto Muraoka and Hiroyuki Yamakawa and Yasuyuki Ohgino and Tomofumi Tanaka and Masatoshi Yoichi and Shinsuke Yuasa and Mitsushige Murata and Makoto Suematsu and Keiichi Fukuda",
year = "2013",
month = "1",
day = "3",
doi = "10.1016/j.stem.2012.09.013",
language = "English",
volume = "12",
pages = "127--137",
journal = "Cell Stem Cell",
issn = "1934-5909",
publisher = "Cell Press",
number = "1",

}

TY - JOUR

T1 - Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes

AU - Tohyama, Shugo

AU - Hattori, Fumiyuki

AU - Sano, Motoaki

AU - Hishiki, Takako

AU - Nagahata, Yoshiko

AU - Matsuura, Tomomi

AU - Hashimoto, Hisayuki

AU - Suzuki, Tomoyuki

AU - Yamashita, Hiromi

AU - Satoh, Yusuke

AU - Egashira, Toru

AU - Seki, Tomohisa

AU - Muraoka, Naoto

AU - Yamakawa, Hiroyuki

AU - Ohgino, Yasuyuki

AU - Tanaka, Tomofumi

AU - Yoichi, Masatoshi

AU - Yuasa, Shinsuke

AU - Murata, Mitsushige

AU - Suematsu, Makoto

AU - Fukuda, Keiichi

PY - 2013/1/3

Y1 - 2013/1/3

N2 - Heart disease remains a major cause of death despite advances in medical technology. Heart-regenerative therapy that uses pluripotent stem cells (PSCs) is a potentially promising strategy for patients with heart disease, but the inability to generate highly purified cardiomyocytes in sufficient quantities has been a barrier to realizing this potential. Here, we report a nongenetic method for mass-producing cardiomyocytes from mouse and human PSC derivatives that is based on the marked biochemical differences in glucose and lactate metabolism between cardiomyocytes and noncardiomyocytes, including undifferentiated cells. We cultured PSC derivatives with glucose-depleted culture medium containing abundant lactate and found that only cardiomyocytes survived. Using this approach, we obtained cardiomyocytes of up to 99% purity that did not form tumors after transplantation. We believe that our technological method broadens the range of potential applications for purified PSC-derived cardiomyocytes and could facilitate progress toward PSC-based cardiac regenerative therapy.

AB - Heart disease remains a major cause of death despite advances in medical technology. Heart-regenerative therapy that uses pluripotent stem cells (PSCs) is a potentially promising strategy for patients with heart disease, but the inability to generate highly purified cardiomyocytes in sufficient quantities has been a barrier to realizing this potential. Here, we report a nongenetic method for mass-producing cardiomyocytes from mouse and human PSC derivatives that is based on the marked biochemical differences in glucose and lactate metabolism between cardiomyocytes and noncardiomyocytes, including undifferentiated cells. We cultured PSC derivatives with glucose-depleted culture medium containing abundant lactate and found that only cardiomyocytes survived. Using this approach, we obtained cardiomyocytes of up to 99% purity that did not form tumors after transplantation. We believe that our technological method broadens the range of potential applications for purified PSC-derived cardiomyocytes and could facilitate progress toward PSC-based cardiac regenerative therapy.

UR - http://www.scopus.com/inward/record.url?scp=84872048038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872048038&partnerID=8YFLogxK

U2 - 10.1016/j.stem.2012.09.013

DO - 10.1016/j.stem.2012.09.013

M3 - Article

C2 - 23168164

AN - SCOPUS:84872048038

VL - 12

SP - 127

EP - 137

JO - Cell Stem Cell

JF - Cell Stem Cell

SN - 1934-5909

IS - 1

ER -